ONYX PHARMACEUTICALS INC 4

Accession 0001181431-13-052525

CIK 0001012140operating

View on SEC.gov Company Profile

Filed

Oct 2, 8:00 PM ET

Accepted

Oct 3, 9:28 PM ET

Size

29.1 KB

Accession

0001181431-13-052525

Insider Transaction Report

Form 4

Period: 2013-10-01

ONYX PHARMACEUTICALS INCONXX

SHEMA SUZANNE M

SVP, General Counsel

Transactions

Disposition from Tender
Common Stock
2013-10-01$125.00/sh−6,468$808,500→ 28,150 total
Disposition to Issuer
Stock Options
2013-10-01−12,472→ 0 total
Exercise: $32.07From: 2010-08-31Exp: 2019-08-31→ Common Stock (12,472 underlying)
Disposition to Issuer
Stock Options
2013-10-01−1,969→ 0 total
Exercise: $30.28From: 2011-03-31Exp: 2020-03-31→ Common Stock (1,969 underlying)
Disposition to Issuer
Stock Options
2013-10-01−16,700→ 0 total
Exercise: $88.86From: 2014-03-28Exp: 2023-03-28→ Common Stock (16,700 underlying)
Disposition to Issuer
Stock Options
2013-10-01−2,157→ 0 total
Exercise: $37.68From: 2013-03-31Exp: 2022-03-30→ Common Stock (2,157 underlying)
Disposition to Issuer
Stock Options
2013-10-01−3,553→ 0 total
Exercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (3,553 underlying)
Disposition to Issuer
Stock Options
2013-10-01−16,510→ 0 total
Exercise: $37.68From: 2013-03-31Exp: 2022-03-31→ Common Stock (16,510 underlying)
Disposition to Issuer
Stock Options
2013-10-01−3,281→ 0 total
Exercise: $30.28From: 2012-03-31Exp: 2021-03-31→ Common Stock (3,281 underlying)
Disposition to Issuer
Stock Options
2013-10-01−1,214→ 0 total
Exercise: $32.07From: 2010-08-31Exp: 2019-08-31→ Common Stock (1,214 underlying)
Disposition to Issuer
Stock Options
2013-10-01−12,489→ 0 total
Exercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (12,489 underlying)
Disposition to Issuer
Stock Options
2013-10-01−903→ 0 total
Exercise: $37.68From: 2013-03-31Exp: 2022-03-30→ Common Stock (903 underlying)
Disposition to Issuer
Stock Options
2013-10-01−24,563→ 0 total
Exercise: $37.68From: 2013-03-30Exp: 2022-03-30→ Common Stock (24,563 underlying)
Disposition to Issuer
Common Stock
2013-10-01$125.00/sh−28,150$3,518,750→ 0 total

Footnotes (2)

[F1]These restricted stock awards were cancelled at the effective time of the merger (the "Merger") pursuant to the Agreement and Plan of Merger, dated August 24, 2013, by and among Onyx Pharmaceuticals, Inc. ("Onyx"), Amgen Inc. and Arena Acquisition Company (the "Merger Agreement") in exchange for an aggregate cash payment equal to the number of shares of Onyx's common stock underlying such restricted stock awards multiplied by the per share purchase price of $125.00. Reflects the forfeiture of 8,575 performance based restricted stock units.
[F2]Represents options to purchase Onyx's common stock that were subject to vesting over time but were cancelled in the Merger in exchange for a cash payment in the amount by which the per share purchase price of $125.00 exceeded the exercise price of the option as of the effective time of the Merger.

Documents

1 file

4
rrd392211.xmlPrimary
FORM 4

Issuer

ONYX PHARMACEUTICALS INC

CIK 0001012140

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001012140

Filing Metadata

Form type: 4
Filed: Oct 2, 8:00 PM ET
Accepted: Oct 3, 9:28 PM ET
Size: 29.1 KB

View on SEC.gov